Skip to main content
AmigoFish

Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs

From The BioCentury Show · · 32 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Vertex’s approach to research, defined over a decade ago to beat the dismal odds of success in biotech, remains core to its strategy, even as the industry evolves and technologies expand. While that strategy, which EVP and CSO David Altshuler calls “serial innovation,” has seen the company launch eight drugs since 2011 and jump market cap tiers (https://www.biocentury.com/article/648865)on the success of its cystic fibrosis portfolio, it’s now being tested in other areas as Vertex expands to pain, renal disease, Type I diabetes, and more. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Altshuler discussed the rising interest in causal biology and the role of AI, noting that the fundamentals of picking targets and programs have not changed.

View full story: https://www.biocentury.com/article/655408

#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment #AI

00:00 - Introduction 02:12 - Causal Biology 08:48 - AI in R&D, at Vertex 16:35 - Academia-Industry Interface 22:00 - Cell Therapy for Diabetes 25:35 - Gene Therapy for DMD

Back to The BioCentury Show · Report a problem